BRMU8603035U - hemodiluted stent with metformin for prevention of intracoronary restenosis - Google Patents

hemodiluted stent with metformin for prevention of intracoronary restenosis

Info

Publication number
BRMU8603035U
BRMU8603035U BRMU8603035-3U BRMU8603035U BRMU8603035U BR MU8603035 U BRMU8603035 U BR MU8603035U BR MU8603035 U BRMU8603035 U BR MU8603035U BR MU8603035 U BRMU8603035 U BR MU8603035U
Authority
BR
Brazil
Prior art keywords
restenosis
hemodiluted
intracoronary
insulin
prevention
Prior art date
Application number
BRMU8603035-3U
Other languages
Portuguese (pt)
Inventor
Walter Junior Santos
Original Assignee
Walter Junior Santos
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Walter Junior Santos filed Critical Walter Junior Santos
Priority to BRMU8603035-3U priority Critical patent/BRMU8603035U/en
Priority to PCT/BR2007/000347 priority patent/WO2008058356A2/en
Publication of BRMU8603035U publication Critical patent/BRMU8603035U/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
    • A61F2/90—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
    • A61F2/91—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
    • A61F2250/0067—Means for introducing or releasing pharmaceutical products into the body

Abstract

A PATENTE DO STENT HEMODILUIDO COM MEDICAMENTO METFORMINA PARA PREVENçãO DE REESTENOSE INTRACORONARIANA, resume-se na combinação de uma endoprotese hemodiluido a um modulador de resistência insulínica, utilizados contra as doenças cardiovasculares que são a principal causa de morte no mundo globalizado. Há nítida correlação entre o ganho ponderal e o excesso de peso com risco de doenças cardiovasculares. O excesso de peso predispõe a estas doenças devido anormalidades no metabolismo dos lípides, glicose e pressão arterial. A resistência à insulina / hiperinsulinemia parece ser um fator de risco independente de outros fatores de risco associados, como a obesidade, hiperlipidemia e hipertensão, tanto em homens como em mulheres. A insulina e os fatores de crescimento semelhantes à insulina estimulam a atividade das células musculares lisas e estão envolvidas na aterogênese e mesmo na reestenose que se segue ao reparo coronário pela angioplastia. Outros efeitos da insulina estão relacionados aos mecanismos que contribuem para o desenvolvimento tanto da hipertensão, hipertrofia miocárdica, proliferação celular, hipertrofia vascular,processos de coagulação, dislipidemia, contribuindo para reestenose intracoronariana pós implante de endaprotese. A PATENTE DO STENT HEMODILUIDO COM MEDICAMENTO METFORMINA PARA PREVENçãO DE REESTENOSE INTRACORONARIANA, diminui sensivelmente este processo deletério vascular, pois, a união da endoprotese com melhoramento do fluxo vascular local, e as funções moduladoras de resistência do medicamento hernodiluido, é a combinação perfeita, para diminuição de eventos cardiovasculares, infarto do miocárdio e morte.HEMODILUTED STENT PATENT WITH METFORMINE MEDICINE FOR PREVENTION OF INTRACORONARY RESTENOSIS is a combination of hemodiluted stenting and insulin resistance modulator used against cardiovascular diseases that are the leading cause of death in the globalized world. There is a clear correlation between weight gain and overweight with risk of cardiovascular disease. Overweight predisposes to these diseases due to abnormalities in lipid metabolism, glucose and blood pressure. Insulin resistance / hyperinsulinemia appears to be a risk factor independent of other associated risk factors such as obesity, hyperlipidemia and hypertension in both men and women. Insulin and insulin-like growth factors stimulate smooth muscle cell activity and are involved in atherogenesis and even restenosis following coronary repair by angioplasty. Other effects of insulin are related to the mechanisms that contribute to the development of both hypertension, myocardial hypertrophy, cell proliferation, vascular hypertrophy, coagulation processes, dyslipidemia, contributing to intracoronary restenosis after endaprotesis implantation. HEMODILUTED STENT PATENT WITH METFORMIN MEDICINE FOR PREVENTION OF INTRACORONARY RESTENOSIS markedly decreases this deleterious vascular process, since the combination of endoprosthesis with local vascular flow improvement, and the resistance modulating functions of the hernodiluid drug, is the perfect combination for decreased cardiovascular events, myocardial infarction and death.

BRMU8603035-3U 2006-11-16 2006-11-16 hemodiluted stent with metformin for prevention of intracoronary restenosis BRMU8603035U (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
BRMU8603035-3U BRMU8603035U (en) 2006-11-16 2006-11-16 hemodiluted stent with metformin for prevention of intracoronary restenosis
PCT/BR2007/000347 WO2008058356A2 (en) 2006-11-16 2007-11-14 Descriptive report of patent of invention of the hemodiluted stent with the medicament metformin for prevention of intracoronary reestenose

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BRMU8603035-3U BRMU8603035U (en) 2006-11-16 2006-11-16 hemodiluted stent with metformin for prevention of intracoronary restenosis

Publications (1)

Publication Number Publication Date
BRMU8603035U true BRMU8603035U (en) 2008-07-01

Family

ID=39545307

Family Applications (1)

Application Number Title Priority Date Filing Date
BRMU8603035-3U BRMU8603035U (en) 2006-11-16 2006-11-16 hemodiluted stent with metformin for prevention of intracoronary restenosis

Country Status (2)

Country Link
BR (1) BRMU8603035U (en)
WO (1) WO2008058356A2 (en)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6846836B2 (en) * 2003-04-18 2005-01-25 Bristol-Myers Squibb Company N-substituted phenylurea inhibitors of mitochondrial F1F0 ATP hydrolase

Also Published As

Publication number Publication date
WO2008058356A2 (en) 2008-05-22
WO2008058356A3 (en) 2009-04-09

Similar Documents

Publication Publication Date Title
Kosuru et al. Pterostilbene decreases cardiac oxidative stress and inflammation via activation of AMPK/Nrf2/HO-1 pathway in fructose-fed diabetic rats
Shukla et al. Pathophysiology of saphenous vein graft failure: a brief overview of interventions
Jin et al. Cardiac H 2 S generation is reduced in ageing diabetic mice
Sun et al. Ginsenoside Rg3 improves cardiac mitochondrial population quality: mimetic exercise training
Dong et al. Alpha-lipoic acid alleviates high-glucose suppressed osteogenic differentiation of MC3T3-E1 cells via antioxidant effect and PI3K/Akt signaling pathway
Park et al. Compound K, a novel ginsenoside metabolite, inhibits adipocyte differentiation in 3T3-L1 cells: involvement of angiogenesis and MMPs
Tan et al. Hyperhomocysteinemia inhibits post-injury reendothelialization in mice
Lee et al. Cytotoxic effects of delphinidin in human osteosarcoma cells
Wang et al. Resveratrol protects osteoblasts against dexamethasone-induced cytotoxicity through activation of AMP-activated protein kinase
FR2856305A1 (en) PROSTHESES WITH BIOLOGICALLY ACTIVE COATINGS
Bhattacharya et al. Free radicals cardiovascular diseases: An update
Zhu et al. Hydrogen sulfide: A new therapeutic target in vascular diseases
Akiyama et al. High glucose-induced upregulation of Rho/Rho-kinase via platelet-derived growth factor receptor− β increases migration of aortic smooth muscle cells
BRMU8603035U (en) hemodiluted stent with metformin for prevention of intracoronary restenosis
Zhen et al. Phytoestrogen α-zearalanol improves vascular function in ovariectomized hyperhomocysteinemic rats
Sadighi et al. Lack of metformin effects on different molecular subtypes of breast cancer under normoglycemic conditions: an in vitro study
Valdesuso et al. The EXTREME registry: Titanium‐nitride‐oxide coated stents in small coronary arteries
Jagtap et al. UCP1 activation: hottest target in the thermogenesis pathway to treat obesity using molecules of synthetic and natural origin
BRMU8602970U (en) medicine "telmisartam + metformin" in combination form for cardiovascular disease
Shunmugam Moringa oleifera crude aqueous leaf extract induces apoptosis in human hepatocellular carcinoma cells via the upregulation of NF-kB and IL-6/STAT3 pathway.
Balistreri et al. Is it the time of seno-therapeutics application in cardiovascular pathological conditions related to ageing?
Andrade et al. Hemodynamic and clinical performance of Solo stentless bioprosthetic aortic valves
BRMU8602991U (en) medicine "candesartan + metformin" in combination form for cardiovascular disease
BRMU8602979U (en) medicine "atorvastatin + metformin" in combination form for cardiovascular disease
BRMU8602968U (en) medicine "ramipril + metformin" in combination form for cardiovascular disease

Legal Events

Date Code Title Description
B03A Publication of an application: publication of a patent application or of a certificate of addition of invention
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE AS 4A E 5A ANUIDADES.

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2156 DE 02/05/2012.